Annals of Otolaryngology Head and Neck Surgery (ISSN 2835-7132) | Volume 3, Issue 3 | Research Article | Open Access DOI
Sant Albors*
Sant Albors. Marta1*, Ferrando Díez. Angélica1, Virós Porcuna. David2, Camara Vallejo. Marina3, Carrasco Lopez. Cristian4, Cots Seignot. Isabel5, Dueso Delgado. Victor3, Garcia Linares. Jordi3, Izquierdo Miranda. Alexandre-Augusto3, Oliva. Anna6, Palau Viames. María del Mar2, Planas Toledano. Isabel7, Puyalto de Pablo. Paloma6, Quer Pi-Sunyer. Ariadna8, Vallejos Arroyo. Virginia9, Vilà Poyatos. Jordi4, Viña Soria. Constanza2, Mesia. Ricard1, Pollán-Guisasola. Carlos2, Cirauqui Cirauqui. Beatriz1*
1Medical Oncology, Institut Català d’Oncologia, Badalona (Barcelona), Spain
2ENT Head ans Neck Surgery, Hospital Germans Trias i Pujol, Badalona (Barcelona), Spain
3Oral and Maxillofacial Surgery, Hospital Germans Trias i Pujol, Badalona (Barcelona), Spain
4Plastic Surgery, Hospital Germans Trias I Pujol, Badalona (Barcelona), Spain
5Nutritionist, Hospital Germans Trias i Pujol, Badalona (Barcelona), Spain
6Radiology, Hospital Germans Trias i Pujol, Badalona (Barcelona), Spain
7Radiation Oncology, Hospital Germans Trias i Pujol, Badalona (Barcelona), Spain
8Anathomical Pathology, Hospital Germans Trias i Pujol, Badalona (Barcelona), Spain
9Nuclear Medicine, Hospital Germans Trias i Pujol, Badalona (Barcelona), Spain
*Correspondence to: Sant Albors
Fulltext PDFObjectives: Our main goal was to assess the impact on overall survival (OS) of the advances in the cornerstone therapies in locoregional recurrence (LRR) of locally advanced squamous cell carcinoma of the head and neck (SCCHN).
Methods: We retrospectively evaluated 56 patients with LRR-SCCHN (2018- 2020) in our hospital. Patients were categorized into 4 groups according to the first treatment (surgery, radiotherapy (RDT), chemotherapy (CT) + cetuximab, immunotherapy (IT)). We included an expansion cohort of patients treated with IT (n=13). A descriptive analysis of patients and disease characteristics and treatments as well as a median OS (mOS) analysis were performed.
Results: The mOS was 24.9 months (mo) [CI 95%: 11.6-38.2]. mOS by subgroup was: 40.4 mo for surgery (n=32), 8.6 mo for RDT (n=8), 10.7 mo for CT+ cetuximab (n=10), and 30 mo for IT (n=3) (p=0.067). The mOS of the expansion cohort was 15 mo. We identified a statistical difference in mOS depending on the residual tumor (p=0.042) in operated patients and performance status (PS) (p=0.009). There was also a statistical difference in mOS depending on whether they received IT (n=14) or not (n=14) in any line (p=0.012).
Conclusion: mOS of SCCHN patients with LRR remains poor despite new therapeutic strategies. Our results suggest that surgery is the best treatment when the tumor can be resected with free margins, especially in patients with prolonged DFS. If local therapy is not possible, an early use of IT should be assessed. Therapeutic decisions should be made by a multidisciplinary team.
Sant Albors. Marta, Ferrando Díez. Angélica, Virós Porcuna. David, Camara Vallejo. Marina, Carrasco Lopez. Cristian, Cots Seignot. Isabel, et al. Impact of Therapeutic Advances in Locoregionally Recurrent Head and Neck Squamous Cell Carcinoma. Annal of Otol Head and Neck Surg. 2024;3(3):1-15.